Aims: To investigate the pathological effects of preoperative chemotherapy on oesophageal carcinoma. Methods: Qualitative and quantitative changes in oesophageal carcinoma after preoperative chemotherapy were assessed by examination of biopsy specimens before treatment and resected specimens.
Results: Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM) , nine showed minor histological changes compared with 14 control cases. All 12 patients with squamous carcinoma treated with preoperative mitomycin, ifosfamide, and cisplatin (MIC) showed noticeable histological changes when compared with the 13 control cases. Changes included complete ablation (n = 1) and partial regression (n = 5) of the tumour. A quantitative estimate of the proportion of tumour to stroma showed no difference between control adenocarcinomas and those treated with chemotherapy. There was, however, a significant reduction (p < 0.01) in the proportion of tumour to stroma in the treated squamous group compared with the controls. There was no relation between the degree of response in squamous carcinomas and the degree of differentiation of the tumour. Patients in which squamous carcinomas responded well, as assessed quantitatively, showed a tendency to better survival at one year. Conclusions: Histopathological changes attributable to chemotherapy can be observed in oesophageal carcinoma. The response of squamous carcinoma to MIC is histologically more evident than that of adenocarcinoma to FAM. A quantitative technique may be useful in assessing the effect of chemotherapy in oesophageal squamous carcinoma. (7 Clin Pathol 1993; 46:51-55) The pathological effects of preoperative chemotherapy in The following comparisons were then made: (a) Pretreatment biopsy and resected specimens in patients treated with chemotherapy (groups 1 and 3). (b) Preoperative biopsy and resected specimens in patients not treated with chemotherapy (groups 2 and 4). (c) Resected specimens in group 1 (adenocarcinomas with chemotherapy) and group 2 (adenocarcinomas without chemotherapy). (d) Resected specimens in group 3 (squamous carcinomas with chemotherapy) and group 4 (squamous carcinomas without chemotherapy).
In addition to a qualitative assessment, a quantitative morphometric measurement was made on the resected specimens to determine the proportion of tumour to stroma. A section was selected from the central area of each tumour, or in the case of grossly ablated tumours, from the centre of the healed area. The densest region of tumour compared with background stroma was located empirically and a submucosal field observed at a magnification of xlO0. A camera lucida permitted simultaneous observation of a movable stylus on a bit pad. The proportion of tumour area to stroma was measured using the digitising tablet system and stylus (Summagraphics Bit Pad Two, Summagraphics Corp., Fairfield, Connecticut, USA). Areas MIC) with resected specimens in group 4 (untreated squamous carcinomas) showed that all 12 tumours in group 3 showed considerable differences from the untreated tumours. In one patient there was complete ablation of the tumour ( fig 1B) ; in five there was pronounced tumour regression, with only minute foci of malignant cells scattered in the submucosa or muscularis propria, frequently surrounded by a mixed chronic inflammatory cell infiltrate ( fig 2B) . All 12 specimens showed a localised fibrotic response and a localised chronic inflammatory cell infiltrate, and 10 showed regeneration of the surface epithelium by a thin stratified squamous layer. The staging of resected specimens by tumour and node status is shown in fig 3 . Groups 1 and 2 showed a similar range of staging, but group 3 patients showed a lower staging when compared with group 4 controls.
By quantitative analysis the mean proportion of tumour to stroma in the adenocarcinomas treated with FAM (group 1) was 73-25% (CI 10-94). This did not differ significantly from that of the untreated adenocarcinomas (group 2) which was 71-56% (CI 12-58). The mean value for the proportion of tumour to stroma in the group of squamous carcinomas treated with MIC (group 3) was 32-54% (CI 16.46) compared with 64-44% (CI 9d13) in the untreated cases. This difference was significant (p < 0 01) (fig 4) . In this group there appeared to be two clearly distinguishable subgroups; one group of six patients (group 3a) where more than 50% of the field consisted of tumour and another group of six patients (group 3b) where less than 19% of the field was occupied. The differentiation of the pretreatment biopsy specimens in these two subgroups was as follows: group 3a contained two poorly, one moderately, and three well differentiated tumours; group 3b contained two poorly, one moderately, and three well differentiated tumours. Numbers are too small for formal statistics but group 3b showed a tendency to better survival at one year-five out of six surviving, with the sixth a postoperative death, compared with three survivors out of six in group 3a, one death being unrelated and two due to recurrence of tumour.
Discussion
The study has shown that qualitative and quantitative responses to chemotherapy can be observed histopathologically in oesophageal cancer. Qualitative and morphometric techniques confirmed that the treatment of adenocarcinomas with FAM (group 1) was much less effective than treatment of squamous carcinomas with MIC (group 3).
Qualitative differences were seen following both chemotherapeutic regimens but were minor in group 1 compared with those in group 3, in both numbers of responders and extent. Previous light microscopic studies have described chemotherapeutic response in terms of the presence or absence of microscopic tumour, necrotic tumour,2 or of necrosis only. There has been one electron microscopic study reporting chemotherapeutic effect in terms of necrotic features of nuclei. be inappropriate as in our experience reduction of tumour bulk in a healing oesophagus leaves small foci of apparently viable tumour with no necrotic areas. The presence of degenerate and necrotic tumour seen in other studies, and occasionally in this study, could be secondary to local ischaemia rather than representing a direct effect of chemotherapy. This discrepancy in results is possibly due to tumours being studied at different intervals following chemotherapy or because more of their data relate to tumours treated by radiotherapy. It is not possible to determine this as the necessary details are not stated in the publication.'0
The morphometric technique used in this study quantitates a partial response to chemotherapy by measuring the actual ratio of tumour to background stroma in the treated groups when compared with the untreated groups. Quantitatively, the proportion of tumour to stroma was not significantly reduced by FAM chemotherapy in adenocarcinoma, despite minor qualitative changes seen in nine out of the 13 patients. The MIC regimen, however, significantly reduced the proportion of tumour to stroma in squamous tumours. In these patients there appeared to be two clearly divided subgroups in terms of degree of response. The numbers are small but it could be that these two subgroups represent a different susceptibility to MIC. The degree of differentiation of the tumour found at pretreatment biopsy bore no relation to susceptibility. Good quantitative responders, however, showed a tendency to improved survival at one year.
The similar staging in the treated and untreated adenocarcinomas confirms the status of group 2 cases as representative controls for group 1, bearing in mind the low level of histopathological response. When comparing the treated squamous carcinomas with their controls, the former showed a lower staging. This is of interest since staging of IIA and better (nine out of 12) represents local node negative patients with invasion into the adventitia or less. This could indicate a reduction in staging as a result of the chemotherapy but cannot be proved in the individual patient as resection is only performed once. The assumption of a chemotherapeutic effect of MIC on squamous carcinoma staging is reasonable as the observed reduction in the ratio of tumour to stroma provides indirect confirmatory evidence. The fact that there was no such lowered staging or reduction in tumour to stroma ratio in the adenocarcinomas treated with FAM also tends to corroborate this.
In conclusion, histopathological changes attributable to chemotherapy can be observed in oesophageal carcinoma. The response of squamous carcinoma to MIC chemotherapy is histologically more evident than that of adenocarcinoma to FAM chemotherapy. Qualitative observation of these changes may provide useful information about the response to chemotherapy, but it is of necessity imprecise and subject to observer bias. Quantitative analysis, particularly in relation to the proporu I tion of tumour to stroma, is a simple technique which is more accurate and extends our ability to evaluate objectively the effect of chemotherapy on squamous carcinoma of the oesophagus.
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